Piper Sandler Maintains Overweight on DexCom, Raises Price Target to $160
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Matt O'Brien maintains an Overweight rating on DexCom (NASDAQ:DXCM) and raises the price target from $150 to $160.
July 28, 2023 | 5:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler maintains an Overweight rating on DexCom and raises the price target from $150 to $160, which could positively impact the stock's price.
The raised price target by Piper Sandler indicates a positive outlook for DexCom. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100